Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Galera Therapeutics, Inc. (GRTX)  
$0.18 0.00 (-0.51%) as of 4:30 Tue 5/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 24,810,000
Market Cap: 4.34(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.0903 - $3.42
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Galera Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of therapeutics that have the potential to transform radiotherapy in cancer. Co. utilizes its capabilities in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Co.'s product candidate, avasopasem manganese, GC4419, is a selective small molecule dismutase mimetic that is developing for the reduction of severe oral mucositis. Co.'s another dismutase mimetic product candidate, GC4711, is to increase the anti-cancer efficacy of stereotactic body radiation therapy.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 2,462,257 3,394,659 3,394,659 3,515,659
Total Buy Value $529,976 $696,393 $696,393 $908,823
Total People Bought 1 1 1 4
Total Buy Transactions 3 9 9 12
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 92
  Page 4 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Schwarzman Stephen A 10% Owner   –       –       •   2019-11-12 4 B $12.00 $3,000,000 I/I 250,000 130,444 1.5     -
   Schwarzman Stephen A 10% Owner   –       –       •   2019-11-12 4 A $0.00 $0 I/I 1,428,984 111,021     -
   Novo A/s SEE REMARKS   –       –       •   2019-11-12 4 B $12.00 $6,000,000 D/D 500,000 3,409,021 2.45     -
   Novo A/s SEE REMARKS   –       –       •   2019-11-12 4 A $0.00 $0 D/D 2,909,021 2,909,021     -
   Sandell Scott D 10% Owner   –       –       •   2019-11-12 4 B $12.00 $4,999,992 D/D 416,666 4,358,047 2.45     -
   Sandell Scott D 10% Owner   –       –       •   2019-11-12 4 A $0.00 $0 D/D 3,941,381 3,941,381     -
   Mehra Anand 10% Owner   –       –       •   2019-11-12 4 B $12.00 $9,000,000 D/D 750,000 3,083,712 2.45     -
   Mehra Anand 10% Owner   –       –       •   2019-11-12 4 A $0.00 $0 D/D 2,333,712 2,333,712     -
   Beardsley Robert A Chief Operating Officer   •       –      –    2019-11-12 4 A $0.00 $0 D/D 15,361 68,191     -
   Novartis Ag 10% Owner   –       –       •   2019-11-12 4 B $12.00 $3,000,000 I/I 250,000 3,543,067 1.5     -
   Novartis Ag 10% Owner   –       –       •   2019-11-12 4 A $0.00 $0 I/I 3,293,067 3,293,067     -
   Buckler Regina A. 10% Owner   –       –       •   2019-11-06 3 IO $0.00 $0 D/D 0 54,258     -
   Keene Jeffrey 10% Owner   –       –       •   2019-11-06 3 IO $0.00 $0 D/D 0 54,258     -
   Sorensen Mel President and CEOOfficer   •       •      –    2019-11-06 3 IO $0.00 $0 D/D 0 15,029     -
   Riley Dennis 10% Owner   –       –       •   2019-11-06 3 IO $0.00 $0 I/I 0 54,258     -
   Matthes Catherine L. 10% Owner   –       –       •   2019-11-06 3 IO $0.00 $0 I/I 0 52,830     -
   Beardsley Robert A Chief Operating OfficerOfficer   •       –      –    2019-11-06 3 IO $0.00 $0 D/D 0 52,830     -

  92 Records found
  1  2  3  4    
  Page 4 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed